Efficacy and safety of doripenem for sepsis with neutropenia in Japanese patients with hematologic diseases

Nobu Akiyama, Akihisa Kanamaru, Kazuo Tamura, Mitsune Tanimoto, Kazuma Ohyashiki, Yasunori Nakagawa, Akio Urabe, Toru Masaoka

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Doripenem (DRPM) is one of the carbapenems which has a broad-spectrum and strong activity against Pseudomonas aeruginosa. This observational study was conducted between April 2006 and March 2007 in Japan to evaluate the efficacy and safety of DRPM 0.5 g three times a day for sepsis with neutropenia in patients with hematologic diseases. One hundred-nineteen patients were enrolled from 34 medical institutes, comprising 117 patients for safety evaluation and 104 for efficacy evaluation. Monotherapy of DRPM 0.5 g three times a day (DRPM monotherapy) was evaluated in 73 patients. The response rates of DRPM monotherapy at 72 hours and at Day 7 were 31.5% (23/73) and 67.1% (49/73), respectively. The incidence of adverse reactions including abnormal changes in laboratory values was 23.1%, and hepatic toxicity was most common. All of these adverse events were judged by the investigators as non-serious and tolerable. These results suggest that DRPM is useful for sepsis with neutropenia, though further study may be warranted.

Original languageEnglish
Pages (from-to)251-262
Number of pages12
JournalJapanese Journal of Antibiotics
Volume65
Issue number4
Publication statusPublished - Aug 2012

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Efficacy and safety of doripenem for sepsis with neutropenia in Japanese patients with hematologic diseases'. Together they form a unique fingerprint.

  • Cite this

    Akiyama, N., Kanamaru, A., Tamura, K., Tanimoto, M., Ohyashiki, K., Nakagawa, Y., Urabe, A., & Masaoka, T. (2012). Efficacy and safety of doripenem for sepsis with neutropenia in Japanese patients with hematologic diseases. Japanese Journal of Antibiotics, 65(4), 251-262.